Aflibercept/rinucumab - Regeneron Pharmaceuticals

Drug Profile

Aflibercept/rinucumab - Regeneron Pharmaceuticals

Alternative Names: Aflibercept/REGN 2176; Eylea/REGN-2176; Eylea/rinucumab; PDGFR-beta-Eylea combination therapy - Bayer/Regeneron; REGN-2176-3; REGN-2176/aflibercept; REGN-2176/Eylea; Rinucumab/aflibercept; Rinucumab/Eylea

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antibodies; Eye disorder therapies; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Placenta growth factor inhibitors; Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Wet age-related macular degeneration

Most Recent Events

  • 16 Feb 2017 Regeneron Pharmaceuticals terminates a phase II trial in Wet age related macular degeneration (In Adults, In the elderly) in USA and Japan (NCT02418754)
  • 01 Dec 2016 Discontinued - Phase-II for Wet age-related macular degeneration (In the elderly, In adults) in USA, Japan (Intravitreous)
  • 30 Sep 2016 Top-line efficacy and safety data from a phase II trial in Wet age-related macular degeneration released by Regeneron Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top